Microstent reduces medication use


Intracanalicular device providing durable IOP reduction as standalone procedure

The open study enrolled 69 patients at 7 centres. Forty eyes underwent microinvasive glaucoma surgery (MIGS) alone and 29 had combination phacoemulsification. After one year of follow-up in both subgroups, both mean IOP and mean medication use were significantly reduced from baseline. No serious complications occurred and there were no cases of device migration or perforation.

"MIGS is an evolving therapeutic option conceived to treat glaucoma surgically more safely than trabeculectomy while still maintaining traditional options," claimed Dr Samuelson, founding partner, Minnesota Eye Consultants, Minneapolis, Minnesota, USA, and medical monitor for the multinational study. "However, the MIGS procedures are often performed in conjunction with cataract extraction, which makes it difficult to know what is the pressure effect from the MIGS procedure itself.

"Not only does the stent occupy nearly 8 mm of Schlemm's canal, providing access for aqueous to multiple collector channels, but it also dilates the canal," Dr Samuelson said. "Laboratory studies have shown that this true stenting further improves aqueous outflow."

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.